2026 Q1 -tulosraportti
67 päivää sitten
‧1 t 2 min
18,00 DKK/osake
Viimeisin osinko
5,37%Tuotto/v
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
Asiakkaat katsoivat myös
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
·15 t sittenHi, does anyone know why it has fallen since March 2024? And is it something you see will grow or continue to fall from today and for the next period?
·53 min sittenFrom Gemini --‐-------‐------------ The Coloplast share has been through a challenging period over the past few years, and the share price decline is due to a combination of specific business setbacks and changed market conditions. Here are the main reasons why the share price has fallen back: ### 1. Challenges in China China has historically been a major growth engine for Coloplast, but the area has recently been characterized by: * **Weakened consumer sentiment:** The aftermath of the pandemic and a general economic slowdown in China have hit sales. * **Product returns:** In 2025, Coloplast carried out an extensive voluntary return of *Biatain Adhesive* bandages in China, which cost millions in lost revenue and created uncertainty. * **Increased local competition:** Chinese manufacturers have become more aggressive, which puts pressure on Coloplast's market share within ostomy and wound care. ### 2. Downgrade of Kerecis expectations In 2023, Coloplast made its largest acquisition ever with Icelandic **Kerecis** (biological wound care) at a price of approx. DKK 8.9 billion. * **Growth slowdown:** Investors had expected growth of around 25%, but in early 2026, this was adjusted downwards to approx. 10%. * **Medicare changes:** Changes in US reimbursement rules (Medicare) for outpatient treatment have created great uncertainty about how quickly Kerecis can grow going forward. ### 3. Normalization of the MedTech sector During and immediately after the pandemic, healthcare stocks were traded at very high prices (multiples). * **Interest rate hikes:** Higher interest rates have generally made investors less willing to pay a premium for growth stocks. * **P/E adjustment:** Coloplast has gone from being a very highly priced stock to a more "normal" pricing. Analysts from Goldman Sachs, among others, downgraded the stock in 2026 due to concerns that historically high earnings (margins) are under pressure. ### 4. Operational bumps and management change * **Logistics in the USA:** The construction of a new distribution center in the USA resulted in unforeseen costs and delivery problems, which affected the results in the *Chronic Care* division. * **CEO change:** After a period with an interim CEO, the company appointed Gavin Wood as the new permanent CEO in March 2026. Although this removes uncertainty, the market is still awaiting his strategy to get growth back on track. **Summary:** Where Coloplast was previously seen as a "safe haven" with stable high growth, the problems in China and the uncertainty surrounding the Kerecis acquisition have made investors doubt whether the company can maintain its historical growth rates. This has led to the significant share price correction we have seen here in 2025 and 2026.
·22 t sittenFree fall since November - terrible management and stock
·2 päivää sittenWhen was the management replaced? When will the tide turn? Coloplast definitely has a debt to pay to the shareholders, and it can't happen soon enough.
·2 päivää sittenGavin Wood starts as CEO at Coloplast on May 1, 2026. So, very soon. However, it is important to remember that he still has the task of understanding the company inside and out, which can take several months for him to make well-considered decisions that benefit COLO most effectively.
·9.4.If Niels. B. Christiansen can do the same with Coloplast as he has done in Danfoss and LEGO, then it will be good. He understands how to wring the synergies out of operations and at the same time have a commercial eye for the future. The question is merely whether he is able to do it from the board, when he is not at the helm. That is quite interesting. I am positive, and will start following the company more closely, and need to have an entry level determined soon. PS. The Pay-out ratio is also starting to look like something.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
2026 Q1 -tulosraportti
67 päivää sitten
‧1 t 2 min
18,00 DKK/osake
Viimeisin osinko
5,37%Tuotto/v
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 t sittenHi, does anyone know why it has fallen since March 2024? And is it something you see will grow or continue to fall from today and for the next period?·53 min sittenFrom Gemini --‐-------‐------------ The Coloplast share has been through a challenging period over the past few years, and the share price decline is due to a combination of specific business setbacks and changed market conditions. Here are the main reasons why the share price has fallen back: ### 1. Challenges in China China has historically been a major growth engine for Coloplast, but the area has recently been characterized by: * **Weakened consumer sentiment:** The aftermath of the pandemic and a general economic slowdown in China have hit sales. * **Product returns:** In 2025, Coloplast carried out an extensive voluntary return of *Biatain Adhesive* bandages in China, which cost millions in lost revenue and created uncertainty. * **Increased local competition:** Chinese manufacturers have become more aggressive, which puts pressure on Coloplast's market share within ostomy and wound care. ### 2. Downgrade of Kerecis expectations In 2023, Coloplast made its largest acquisition ever with Icelandic **Kerecis** (biological wound care) at a price of approx. DKK 8.9 billion. * **Growth slowdown:** Investors had expected growth of around 25%, but in early 2026, this was adjusted downwards to approx. 10%. * **Medicare changes:** Changes in US reimbursement rules (Medicare) for outpatient treatment have created great uncertainty about how quickly Kerecis can grow going forward. ### 3. Normalization of the MedTech sector During and immediately after the pandemic, healthcare stocks were traded at very high prices (multiples). * **Interest rate hikes:** Higher interest rates have generally made investors less willing to pay a premium for growth stocks. * **P/E adjustment:** Coloplast has gone from being a very highly priced stock to a more "normal" pricing. Analysts from Goldman Sachs, among others, downgraded the stock in 2026 due to concerns that historically high earnings (margins) are under pressure. ### 4. Operational bumps and management change * **Logistics in the USA:** The construction of a new distribution center in the USA resulted in unforeseen costs and delivery problems, which affected the results in the *Chronic Care* division. * **CEO change:** After a period with an interim CEO, the company appointed Gavin Wood as the new permanent CEO in March 2026. Although this removes uncertainty, the market is still awaiting his strategy to get growth back on track. **Summary:** Where Coloplast was previously seen as a "safe haven" with stable high growth, the problems in China and the uncertainty surrounding the Kerecis acquisition have made investors doubt whether the company can maintain its historical growth rates. This has led to the significant share price correction we have seen here in 2025 and 2026.
- ·22 t sittenFree fall since November - terrible management and stock
- ·2 päivää sittenWhen was the management replaced? When will the tide turn? Coloplast definitely has a debt to pay to the shareholders, and it can't happen soon enough.·2 päivää sittenGavin Wood starts as CEO at Coloplast on May 1, 2026. So, very soon. However, it is important to remember that he still has the task of understanding the company inside and out, which can take several months for him to make well-considered decisions that benefit COLO most effectively.
- ·9.4.If Niels. B. Christiansen can do the same with Coloplast as he has done in Danfoss and LEGO, then it will be good. He understands how to wring the synergies out of operations and at the same time have a commercial eye for the future. The question is merely whether he is able to do it from the board, when he is not at the helm. That is quite interesting. I am positive, and will start following the company more closely, and need to have an entry level determined soon. PS. The Pay-out ratio is also starting to look like something.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt
Asiakkaat katsoivat myös
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
2026 Q1 -tulosraportti
67 päivää sitten
‧1 t 2 min
Uutiset
Tämän sivun uutiset ja/tai sijoitussuositukset tai otteet niistä sekä niihin liittyvät linkit ovat mainitun tahon tuottamia ja toimittamia. Nordnet ei ole osallistunut materiaalin laatimiseen, eikä ole tarkistanut sen sisältöä tai tehnyt sisältöön muutoksia. Lue lisää sijoitussuosituksista.
Yhtiötapahtumat
Datan lähde: FactSet, Quartr| Seuraava tapahtuma | |
|---|---|
2026 Q2 -tulosraportti 12.5. |
| Menneet tapahtumat | ||
|---|---|---|
2026 Q1 -tulosraportti 6.2. | ||
Vuosittainen yhtiökokous 2025 4.12.2025 | ||
2025 Q4 -tulosraportti 4.11.2025 | ||
2025 Q3 -tulosraportti 19.8.2025 | ||
2025 Q2 -tulosraportti 6.5.2025 |
18,00 DKK/osake
Viimeisin osinko
5,37%Tuotto/v
Shareville
Liity keskusteluun SharevillessäShareville on aktiivisten yksityissijoittajien yhteisö, jossa voit seurata muiden asiakkaiden kaupankäyntiä ja omistuksia.
Kirjaudu
- ·15 t sittenHi, does anyone know why it has fallen since March 2024? And is it something you see will grow or continue to fall from today and for the next period?·53 min sittenFrom Gemini --‐-------‐------------ The Coloplast share has been through a challenging period over the past few years, and the share price decline is due to a combination of specific business setbacks and changed market conditions. Here are the main reasons why the share price has fallen back: ### 1. Challenges in China China has historically been a major growth engine for Coloplast, but the area has recently been characterized by: * **Weakened consumer sentiment:** The aftermath of the pandemic and a general economic slowdown in China have hit sales. * **Product returns:** In 2025, Coloplast carried out an extensive voluntary return of *Biatain Adhesive* bandages in China, which cost millions in lost revenue and created uncertainty. * **Increased local competition:** Chinese manufacturers have become more aggressive, which puts pressure on Coloplast's market share within ostomy and wound care. ### 2. Downgrade of Kerecis expectations In 2023, Coloplast made its largest acquisition ever with Icelandic **Kerecis** (biological wound care) at a price of approx. DKK 8.9 billion. * **Growth slowdown:** Investors had expected growth of around 25%, but in early 2026, this was adjusted downwards to approx. 10%. * **Medicare changes:** Changes in US reimbursement rules (Medicare) for outpatient treatment have created great uncertainty about how quickly Kerecis can grow going forward. ### 3. Normalization of the MedTech sector During and immediately after the pandemic, healthcare stocks were traded at very high prices (multiples). * **Interest rate hikes:** Higher interest rates have generally made investors less willing to pay a premium for growth stocks. * **P/E adjustment:** Coloplast has gone from being a very highly priced stock to a more "normal" pricing. Analysts from Goldman Sachs, among others, downgraded the stock in 2026 due to concerns that historically high earnings (margins) are under pressure. ### 4. Operational bumps and management change * **Logistics in the USA:** The construction of a new distribution center in the USA resulted in unforeseen costs and delivery problems, which affected the results in the *Chronic Care* division. * **CEO change:** After a period with an interim CEO, the company appointed Gavin Wood as the new permanent CEO in March 2026. Although this removes uncertainty, the market is still awaiting his strategy to get growth back on track. **Summary:** Where Coloplast was previously seen as a "safe haven" with stable high growth, the problems in China and the uncertainty surrounding the Kerecis acquisition have made investors doubt whether the company can maintain its historical growth rates. This has led to the significant share price correction we have seen here in 2025 and 2026.
- ·22 t sittenFree fall since November - terrible management and stock
- ·2 päivää sittenWhen was the management replaced? When will the tide turn? Coloplast definitely has a debt to pay to the shareholders, and it can't happen soon enough.·2 päivää sittenGavin Wood starts as CEO at Coloplast on May 1, 2026. So, very soon. However, it is important to remember that he still has the task of understanding the company inside and out, which can take several months for him to make well-considered decisions that benefit COLO most effectively.
- ·9.4.If Niels. B. Christiansen can do the same with Coloplast as he has done in Danfoss and LEGO, then it will be good. He understands how to wring the synergies out of operations and at the same time have a commercial eye for the future. The question is merely whether he is able to do it from the board, when he is not at the helm. That is quite interesting. I am positive, and will start following the company more closely, and need to have an entry level determined soon. PS. The Pay-out ratio is also starting to look like something.
Yllä olevat kommentit ovat peräisin Nordnetin sosiaalisen verkoston Sharevillen käyttäjiltä, eikä niitä ole muokattu eikä Nordnet ole tarkastanut niitä etukäteen. Ne eivät tarkoita, että Nordnet tarjoaisi sijoitusneuvoja tai sijoitussuosituksia. Nordnet ei ota vastuuta kommenteista.
Tarjoustasot
Nasdaq Copenhagen
Määrä
Osto
-
Myynti
Määrä
-
Viimeisimmät kaupat
| Aika | Hinta | Määrä | Ostaja | Myyjä |
|---|---|---|---|---|
| - | - | - | - |
Välittäjätilasto
Dataa ei löytynyt